Authors: Jonathan Herring, Kirsten Johnson, and Jörg Richstein
Summary
The European Fragile X Network, which consists of seventeen different national fragile X associations, met in Wroclaw, Poland, November 2021, and agreed to work towards the eradication of the word “retardation” in regard to the naming of the Fragile X gene and protein. Emma describes it best, “For this life-changing experience to be distorted with an outdated and derogatory label such as ‘mental retardation’ is a tragedy.” Having “retarded,” a term that was medically acceptable for what we now call “intellectual disability”, as a part of the Fragile X gene and protein name is highly offensive and inappropriate.
The authors explain the three dangers that can arise with this labeling, including stigmatization and the inaccuracy and/or over-focus that causes the name to be misleading.
The use of the word “retardation” is highly stigmatic. Having that word as part of the names may invoke a range of negative emotions from families and individuals living with Fragile X and it invites potentially bullying or negative assumptions from their peers, medical providers, and members of society.
Including this term in the gene and protein name is misleading because it is inaccurate. All people walk around with the FMR1 gene and FMRP is a necessary protein. While the full understanding of the protein is still being developed, it is already known to assist the brain in making connections between cells through synapses, where communication between cells take place. FMRP is present all over the body, so isolating the description to the brain is inaccurate. The authors write, “This is similar to describing the brain as the dementia organ.”
Including this term in the gene and protein name is also misleading because it is over-focused. While many individuals with Fragile X do have intellectual disabilities, this is not the only symptom, nor the defining characteristic, of these individuals. There are also physical and behavioral symptoms associated with Fragile X. Reducing Fragile X to a single characteristic is over-focused and ignores the other challenges and strengths associated with Fragile X.
Following the release of this opinion piece and conversations with HUGO (Human Gene Organisation) Gene Nomenclature Committee, “mental retardation” has been successfully eradicated from labels describing the genetic development of Fragile X syndrome and Fragile X premutation conditions/disorders. The renamed genes are as follows:
FRAXA: Fragile x site, folic acid type, rare, fra(X) (Q7.3) A
FMR1: Fragile x messenger ribonucleoprotein 1
Since the publication of the article, the Fragile X protein name is also in the process of being updated to remove reference to “mental retardation”. The acronyms for the Fragile X gene, FMR1, and protein, FMRP, will remain the same, but no longer carry the heavy, inaccurate weight of an outdated term.
Why This Matters
Next Steps
Following the change to the FMR1 gene name, the Fragile X protein name will also change formally in July 2022 to Fragile X messenger ribonucleoprotein 1. The new name is approved to circulated in the meantime. We are all hopeful that all future publications and references include the updated terminology.
FOR MORE DETAILS VISIT:
The Use of “Retardation” in FRAXA, FMRP, FMR1 and Other Designations or read the summary article, Eradication of ‘mental retardation’ from language describing Fragile X Conditions, on the Fragile X Society’s website.
Herring J, Johnson K, Richstein J. The Use of “Retardation” in FRAXA, FMRP, FMR1 and Other Designations. Cells. 2022; 11(6):1044. https://doi.org/10.3390/cells11061044
more research results
Exploring Parents’ Concerns Regarding Long-Term Support and Living Arrangements for Their Children with Fragile X Syndrome
Given the limited data regarding future planning specific to individuals with Fragile X Syndrome (FXS) and the growing population of this community, this study sought to explore the concerns and challenges caregivers of individuals affected by FXS encounter when considering long-term support plans.
Long-Term Follow-Up of Telehealth-Enabled Behavioral Treatment for Challenging Behaviors in Boys with Fragile X Syndrome
This study showed the significant impact that behavioral treatments can have on rates of challenging behaviors commonly exhibited by boys with FXS, particularly when parents are coached to implement the intervention with their child via telehealth.
Parent and Caregiver Perspectives towards Cannabidiol as a Treatment for Fragile X Syndrome
Some caregivers and parents of individuals with FXS have given CBD supplements to the individuals they care for and learning about their insights and experiences is important. This was the first study to learn more about their observations and opinions regarding CBD to treat FXS.
Observable Symptoms of Anxiety in Individuals with Fragile X Syndrome: Parent and Caregiver Perspectives
Most individuals with FXS cannot state themselves that they are anxious and self-report is needed in current standardized assessments. The information analyzed in this study will result in the development of a measure where observable and quantifiable data on anxiety in those with FXS can become an outcome measure to be used in future research/trials.
Featured image by Clker-Free-Vector-Images↗ from Pixabay↗